Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials

详细信息    查看全文

• 作者：W. Joseph Herring^a ; ^{william_herring@merck.com" class="auth_mail" title="E-mail the corresponding author} ; Kathryn M. Connor^a ; Neely Ivgy-May^a ; Ellen Snyder^a ; Ken Liu^a ; Duane B. Snavely^a ; Andrew D. Krystal^b ; James K. Walsh^c ; Ruth M. Benca^d ; Russell Rosenberg^e ; R. Bart Sangal^f ; Kerry Budd^a ; Jill Hutzelmann^a ; Heather Leibensperger^a ; Samar Froman^a ; Christopher Lines^a ; Thomas Roth^g ; David Michelson^a
• 关键词：Insomnia ; Orexin ; Pharmacotherapy ; Randomized controlled trial ; Sleep ; Suvorexant
• 刊名：Biological Psychiatry
• 出版年：2016
• 出版时间：15 January 2016
• 年：2016
• 卷：79
• 期：2
• 页码：136-148
• 全文大小：402 K

文摘

Suvorexant is an orexin receptor antagonist for treatment of insomnia. We report results from two pivotal phase 3 trials.

Methods

Two randomized, double-blind, placebo-controlled, parallel-group, 3-month trials in nonelderly (18–64 years) and elderly (≥65 years) patients with insomnia. Suvorexant doses of 40/30 mg (nonelderly/elderly) and 20/15 mg (nonelderly/elderly) were evaluated. The primary focus was 40/30 mg, with fewer patients randomized to 20/15 mg. There was an optional 3-month double-blind extension in trial 1. Each trial included a 1-week, randomized, double-blind run-out after double-blind treatment to assess withdrawal/rebound. Efficacy was assessed at week 1, month 1, and month 3 by patient-reported subjective total sleep time and time to sleep onset and in a subset of patients at night 1, month 1, and month 3 by polysomnography end points of wakefulness after persistent sleep onset and latency to onset of persistent sleep (LPS). One thousand twenty-one patients were randomized in trial 1 and 1019 patients in trial 2.

Results

Suvorexant 40/30 mg was superior to placebo on all subjective and polysomnography end points at night 1/week 1, month 1, and month 3 in both trials, except for LPS at month 3 in trial 2. Suvorexant 20/15 mg was superior to placebo on subjective total sleep time and wakefulness after persistent sleep onset at night 1/week 1, month 1, and month 3 in both trials and at most individual time points for subjective time to sleep onset and LPS in each trial. Both doses of suvorexant were generally well tolerated, with <5% of patients discontinuing due to adverse events over 3 months. The results did not suggest the emergence of marked rebound or withdrawal signs or symptoms when suvorexant was discontinued.

Conclusions

Suvorexant improved sleep onset and maintenance over 3 months of nightly treatment and was generally safe and well tolerated.